This is a review about p50, based on 76 published articles (read how Labome selects the articles), using p50 antibody in all methods. It is aimed to help Labome visitors find the most suited p50 antibody.
p50 synonym: EBP-1; KBF1; NF-kB1; NF-kappa-B; NF-kappaB; NFKB-p105; NFKB-p50; NFkappaB; p105; p50; DNA binding factor KBF1; DNA-binding factor KBF1; NF-kappabeta; nuclear factor NF-kappa-B p105 subunit; nuclear factor NF-kappa-B p50 subunit; nuclear factor kappa-B DNA binding subunit

Santa Cruz BiotechnologySanta Cruz Biotechnology p50 product
  • ChIP assayIn 2010, Wei Li et al. employed Santa Cruz Biotechnology p50 antibody to perform ChIP assay in order to show that viral replication was inhibited by the elevated IL-32 levels during influenza virus infections [ncbi , more ]. In 2009, Xiaoping Chen et al. applied Santa Cruz Biotechnology p50 antibody to demonstrate that RelB functions as a dual transcription regulator during endotoxin tolerance [ncbi , more ]. Alessio Iannetti et al. used Santa Cruz Biotechnology p50 antibody to identify NF-kappaB target genes involved in thyroid cancer [ncbi , more ] in 2008 and Sabine Wolter et al. used Santa Cruz Biotechnology p50 antibody to study the contribution of c-Jun to ccl2 transcriptional regulation in genetically modified mouse fibroblasts and in human cells (catalog: sc-114) [ncbi , more ]. In 2007, Natalie J Thornburg et al. utilized Santa Cruz Biotechnology p50 antibody to study the role of NF-kappaB p50 and Bcl-3 in LMP1-mediated upregulation of EGFR in human cervical carcinoma cells [ncbi , more ]. In 2006, Kazi Nazrul Islam et al. employed Santa Cruz Biotechnology p50 antibody to study the effects of oxygen on cyclic AMP and interleukin-1 stimulation of surfactant protein A gene expression [ncbi , more ].
  • ELISAIn 2007, Naoko Kanda et al. employed Santa Cruz Biotechnology p50 antibody to examine the in vitro effects of IL-18 on IFN-gamma-induced CXCL9, CXCL10, and CXCL11 production in human keratinocytes [ncbi , more ].
  • EMSAIn 2009, Derek S Wheeler et al. used Santa Cruz Biotechnology p50 antibody to demonstrate whether Hsp72 is released from virally infected airway epithelial cells resulting in the recruitment and activation of neutrophils [ncbi , more ]. In 2008, Karen G Calfee-Mason et al. applied Santa Cruz Biotechnology p50 antibody to demonstrate that the effects of vitamin E on cell growth parameters do not solely through decreased NF-kappaB activation [ncbi , more ]. Santa Cruz Biotechnology p50 antibody was applied in 2007 to perform EMSA in order to study the transcriptional regulation of PTHrP in ATLL cells by NF-kB (catalog: sc-114) [ncbi , more ], to study the characterization of the human intestinal CD98 promoter and its regulation by interferon-gamma [ncbi , more ]and to study the role of NF-kappaB p50 and Bcl-3 in LMP1-mediated upregulation of EGFR in human cervical carcinoma cells [ncbi , more ]. Santa Cruz Biotechnology p50 antibody was used in 2006 to study the role for the effect of human papillomavirus Type 16 E6 on NF-kappaB activation and cIAP-2 expression in protecting from apoptosis in primary human airway epithelial cells [ncbi , more ], to study the role for protein methyltransferase 2 in inhibiting NF-kappaB function and promoting apoptosis in human kidney cell line 293 [ncbi , more ], to study the role for IL-1 receptor-associated kinase 1 in latent membrane protein 1-induced p65/RelA serine 536 phosphorylation and NF-kappaB activation in human I1A 293 cells [ncbi , more ], to study the effect of attenuated poxvirus vector NYVAC on apoptotic genes and NF-kappaB-responsive genes in infected HeLa cells [ncbi , more ]and to determine the effects of A3AR modulation on mortality and hepatic and renal dysfunction in a murine model of sepsis [ncbi , more ]. In 2004, Chun Fung Chan et al. used Santa Cruz Biotechnology p50 antibody to study the NF-kappaB activation, uPA up-regulation, and hepatitis B viral X protein (HBx) expression in human hepatocellular carcinoma (HCC) and their clinicopathological significance [ncbi , more ]. Santa Cruz Biotechnology p50 antibody was employed in 2003 to study the role for estrogen withdrawal-induced NF-kappaB activity and Bcl-3 expression in growth and hormone independence in human breast cancer cells [ncbi , more ], to study the HSP27 as a ubiquitin-binding protein involved in I-kappaB alpha proteasomal degradation [ncbi , more ], to study the Stat3 expression, localization, and activity in alcoholic liver disease (ALD) in humans [ncbi , more ], to study RANTES expression regulation by plasma membrane CFTR [ncbi , more ]and to study the roles for basic fibroblast growth factor and fenofibric acid in induction and modulation of tissue factor expression in human endothelial cells [ncbi , more ]. Santa Cruz Biotechnology p50 antibody was employed in 2002 to study the role of NF-kappaB in prostate cancer progression in human cells (catalog: SC-114,SC-1190) [ncbi , more ], to study the stimulation of IRF-7 expression by 12-O-tetradecanoylphorbol-13-acetate (TPA) and tumor necrosis factor alpha (TNFalpha) in human peripheral blood monocytes [ncbi , more ]and to study the effect of transforming growth factor- 1 (TGF- 1) on human type II collagen gene expression in articular chondrocytes and the relationship of it with Sp3/Sp1 ratio [ncbi , more ]. In 2001, M Ruiz-Ortega et al. used Santa Cruz Biotechnology p50 antibody to detect the activity of NF-kappaB in the kidney cortex of AngII-infused rats and HeLa cell nuclear extracts [ncbi , more ].
  • immunocytochemistryIn 2008, Pilar Gallel et al. applied Santa Cruz Biotechnology p50 antibody to perform immunocytochemistry in order to study the activation of NF-kappa B in correlation with RET mutational status (catalog: sc-109) [ncbi , more ].
  • immunohistochemistryIn 2005, Sewon Kang et al. utilized Santa Cruz Biotechnology p50 antibody to study the role for activated transcription factors nuclear factor-kappaB and activator protein-1 in inflammation and extracellular matrix degradation in inflammatory acne lesions in vivo in skin cryosections from patients [ncbi , more ]. In 2004, Sergio Mezzano et al. used Santa Cruz Biotechnology p50 antibody to study NF-kappaB in human diabetic nephropathy (catalog: sc-1191) [ncbi , more ].
  • immunoprecipitationSerena Ghisletti et al. used Santa Cruz Biotechnology p50 antibody to investigate the role of NCoR/SMRT interactions in the regulation of inflammatory and anti-inflammatory signals in immunity and homeostasis [ncbi , more ] in 2009 and I Paz-Priel et al. used Santa Cruz Biotechnology p50 antibody to carry out western blot analysis and CHIP assays in order to investigate the mechanism for oncoprotein C/EBPa cooperated with NF-kB p50 to inhibit apoptosis [ncbi , more ]. In 2007, Natalie J Thornburg et al. utilized Santa Cruz Biotechnology p50 antibody to study the role of NF-kappaB p50 and Bcl-3 in LMP1-mediated upregulation of EGFR in human cervical carcinoma cells [ncbi , more ]. Mary H Ritchie et al. applied Santa Cruz Biotechnology p50 antibody to study the role for NF-kappaB binding motifs in the differential induction of chemokine gene expression in human corneal epithelial cells [ncbi , more ] in 2004 and Shai Cohen et al. used Santa Cruz Biotechnology p50 antibody to study the role for IKKbeta in mediating both processing and degradation of p105 in COS-7 cells with human p105 [ncbi , more ]. Santa Cruz Biotechnology p50 antibody was applied in 2003 to study the effect of upregulation of HMG1 on melanoma inhibitory activity expression in malignant melanoma cells [ncbi , more ], to detect p50 in Jurkat cells and HeLa cells [ncbi , more ]and to study the role of RelB serine 368 for dimerization and p100 stabilization [ncbi , more ]. In 2002, Pascal Knuefermann et al. employed Santa Cruz Biotechnology p50 antibody to study the role for myotrophin/V-1 in modulating the levels of activated NF B dimers in human HeLa cells [ncbi , more ].
  • western blotSanta Cruz Biotechnology p50 antibody was utilized in 2009 to demonstrate that the high expression of BCL3 at the time of diagnosis is associated with inferior prognosis (catalog: sc-8414) [ncbi , more ], to investigate the role of PARP-1 in the NF-kB signalling cascade induced by ionizing radiation [ncbi , more ], to carry out western blot analysis and CHIP assays in order to investigate the mechanism for oncoprotein C/EBPa cooperated with NF-kB p50 to inhibit apoptosis [ncbi , more ]and to study that TLR4-activated NF-kB rapidly increases the expression of miR-9 that operates a feedback control of the NF-kB-dependent responses by fine tuning the expression of a key member of the NF-kB family [ncbi , more ]. Santa Cruz Biotechnology p50 antibody was utilized in 2008 to perform western blot in order to study how genistein regulate tumor suppressor genes in prostate cancer cells [ncbi , more ], to study the potential binding partners to Cot and their region of association by separating proteins that were pulled-down with various Cot constructs following immunoprecipiation in human HEK293 cells and Hela cells [ncbi , more ]and to perform western blot in order to study the association between ING4 and the activity of NF-kappa B molecules bound with target gene promoters [ncbi , more ]. Natalie J Thornburg et al. utilized Santa Cruz Biotechnology p50 antibody to study the role of NF-kappaB p50 and Bcl-3 in LMP1-mediated upregulation of EGFR in human cervical carcinoma cells [ncbi , more ] in 2007 and Yutao Yan et al. used Santa Cruz Biotechnology p50 antibody to study the characterization of the human intestinal CD98 promoter and its regulation by interferon-gamma [ncbi , more ]. Santa Cruz Biotechnology p50 antibody was used in 2006 to study the role for protein methyltransferase 2 in inhibiting NF-kappaB function and promoting apoptosis in human kidney cell line 293 [ncbi , more ], to study the effects of oxygen on cyclic AMP and interleukin-1 stimulation of surfactant protein A gene expression [ncbi , more ], to study the effect of attenuated poxvirus vector NYVAC on apoptotic genes and NF-kappaB-responsive genes in infected HeLa cells [ncbi , more ]and to demonstrate that arrestin-2 and GRK5 (G protein-coupled receptor kinase 5) play a negative role in TLR4 signaling in Raw264.7 macrophages [ncbi , more ]. Santa Cruz Biotechnology p50 antibody was used in 2005 to study the CDX1 as an important molecular mediator of Barrett's metaplasia [ncbi , more ], to study the molecular mechanisms in enhancing the resistance to infectious microorganisms by disrupting the uncoupling protein-2 gene [ncbi , more ]and to study the role of endothelin-1 in increaseing total peripheral resistance (TPR) and decreaseing organ blood flow [ncbi , more ]. Santa Cruz Biotechnology p50 antibody was used in 2004 to study the role for NF-kappaB binding motifs in the differential induction of chemokine gene expression in human corneal epithelial cells [ncbi , more ], to study the survival effect of tumour necrosis factor-alpha in human neutrophils [ncbi , more ], to study the identification and characterization of a novel ZU5 and death domain-containing protein designated ZUD in human 293 cells [ncbi , more ], to study the role for IKKbeta in mediating both processing and degradation of p105 in COS-7 cells with human p105 [ncbi , more ]and to study GR-mediated transrepression of the transcription factors AP-1 and NF-B through Trip6 [ncbi , more ]. Santa Cruz Biotechnology p50 antibody was utilized in 2003 to study the role of RelB serine 368 for dimerization and p100 stabilization [ncbi , more ], to study the effect of upregulation of HMG1 on melanoma inhibitory activity expression in malignant melanoma cells [ncbi , more ], to demonstrate that the decrease in CD14 surface expression after GA treatment is due to rapid internalization without new replacement [ncbi , more ], to detect p50 in Jurkat cells and HeLa cells [ncbi , more ]and to study the role for estrogen withdrawal-induced NF-kappaB activity and Bcl-3 expression in growth and hormone independence in human breast cancer cells [ncbi , more ]. Santa Cruz Biotechnology p50 antibody was applied in 2002 to study the role of NF-kappaB in prostate cancer progression in human cells (catalog: SC-114,SC-1190) [ncbi , more ], to study the biological function of nerve growth factor in the regulation of dopamine D2 receptor expression [ncbi , more ]and to stduy the role of IL-11 in human vascular smooth muscle cell proliferation [ncbi , more ].
EMD MilliporeEMD Millipore p50 product
  • EMSAIn 2001, M Ruiz-Ortega et al. used EMD Millipore p50 antibody to detect the activity of NF-kappaB in the kidney cortex of AngII-infused rats and HeLa cell nuclear extracts [ncbi , more ].
  • western blotIn 2007, Meilang Xue et al. applied EMD Millipore p50 antibody to determine the major cell type (s) that EPCR is associated with and whether EPCR functions to mediate the effects of activated protein C (APC) on these cells [ncbi , more ]. In 2006, Jing Mi et al. employed EMD Millipore p50 antibody to study the effect of H1 RNA polymerase III promoter-driven expression of an RNA aptamer on intracellular protein activity in human cells [ncbi , more ]. In 2004, Lea Madi et al. applied EMD Millipore p50 antibody to compare the expression of A3 adenosine receptor in tumor versus normal cells [ncbi , more ].
Cell Signaling TechnologyCell Signaling Technology p50 product
  • EMSAIn 2010, Saira Ali et al. applied Cell Signaling Technology p50 antibody to carry out western blot analysis and EMSA assays in order to investigate the role for NF-kB signalling in the interleukin-1 induced expression of C/EBP delta [ncbi , more ].
  • immunocytochemistryIn 2004, Jongmin Lee et al. employed Cell Signaling Technology p50 antibody to study precise mechanism by which TGase 2 promotes inflammation [ncbi , more ].
  • western blotIn 2010, Saira Ali et al. applied Cell Signaling Technology p50 antibody to carry out western blot analysis and EMSA assays in order to investigate the role for NF-kB signalling in the interleukin-1 induced expression of C/EBP delta [ncbi , more ]. In 2009, Takashi Kobayashi et al. applied Cell Signaling Technology p50 antibody to study the role for TRAF6 in T cell-dependent and T cell-independent humoral immune responses [ncbi , more ]. Celine Cosseau et al. used Cell Signaling Technology p50 antibody to identify host genes specifically targeted by K12 by comparing their responses with responses elicited by pathogens [ncbi , more ] in 2008 and Xiaoyong Bao et al. used Cell Signaling Technology p50 antibody to perform western blot in order to study the role of human metapneumovirus glycoprotein G in innate immune responses [ncbi , more ]. In 2007, Mathias Laga et al. used Cell Signaling Technology p50 antibody to show that methylglyoxal inhibits TNF-induced NF-kappaB DNA binding and NF-kappaB-dependent reporter gene expression in a concentration-dependent manner [ncbi , more ]. In 2006, Nobutaka Suzuki et al. used Cell Signaling Technology p50 antibody to study the role for the innate immune signaling molecule IRAK-4 in T cell activation [ncbi , more ]. Jongmin Lee et al. employed Cell Signaling Technology p50 antibody to study precise mechanism by which TGase 2 promotes inflammation [ncbi , more ] in 2004 and Deok Soo Son et al. used Cell Signaling Technology p50 antibody to determine SAA3 in whole-cell homogenates induced by TNF [ncbi , more ].
Enzo Life SciencesEnzo Life Sciences p50 product
  • western blotIn 2010, Junfang Wu et al. utilized Enzo Life Sciences p50 antibody to investigate the role of PKCdelta in the regulation of CHL1 expression in cultured astrocytes. [ncbi , more ]. In 2008, Patricia Méndez-Samperio et al. applied Enzo Life Sciences p50 antibody to study the role of TLR2 in CCL5 secretion in response to M. bovis BCG [ncbi , more ].
Active MotifActive Motif p50 product
  • western blotIn 2001, A M Al-Zoubi et al. utilized Active Motif p50 antibody to study the role of IG20 in TNF--induced apoptosis and activation of caspase-8 and 3 [ncbi , more ].
Life Technologies CorporationLife Technologies Corporation p50 product
  • western blotIn 2005, Fengjun Wang et al. used Life Technologies Corporation p50 antibody to study intestinal epithelial barrier dysfunction by interferon gamma and tumor necrosis factor alpha [ncbi , more ].
Rockland Immunochemicals, Inc.Rockland Immunochemicals, Inc. p50 product
  • EMSAIn 2007, Yutaka Kida et al. applied Rockland Immunochemicals, Inc. p50 antibody to study the role for protease-activated receptor 2 in serratia marcescens serralysin induced inflammatory responses in human cell lines [ncbi , more ]. Yutaka Kida et al. utilized Rockland Immunochemicals, Inc. p50 antibody to study the roles for AP-1 and C/EBPbeta in the regulation of inducible granulysin gene expression in a human monocytic cell line THP-1 [ncbi , more ] in 2002 and Sergio D Catz et al. used Rockland Immunochemicals, Inc. p50 antibody to study the transcriptional activition of JFC1 by nuclear factor-kB and its regulation by tumour necrosis factor a in prostate carcinoma cells [ncbi , more ].
  • western blotIn 2002, Sergio D Catz et al. applied Rockland Immunochemicals, Inc. p50 antibody to study the transcriptional activition of JFC1 by nuclear factor-kB and its regulation by tumour necrosis factor a in prostate carcinoma cells [ncbi , more ].
EpitomicsEpitomics p50 product
  • western blotIn 2009, Chad Myskiw et al. used Epitomics p50 antibody to carry out western blot analysis in order to investigate the mechanism for vaccinia virus double-stranded RNA binding protein E3 inhibiting the expression of cytokines [ncbi , more ]. In 2007, M V P Nadella et al. utilized Epitomics p50 antibody to perform western blot in order to study the transcriptional regulation of PTHrP in ATLL cells by NF-kB [ncbi , more ].
AbcamAbcam p50 product
  • EMSAIn 2005, Jinke Wang et al. employed Abcam p50 antibody to study a new, general, inexpensive FRET-based approach for assaying sequence-specific DNA-binding proteins in human HeLa cell [ncbi , more ].
  • immunohistochemistryIn 2006, Sameer S Talwalkar et al. utilized Abcam p50 antibody to demonstrate that MALT1 gene rearrangements are absent or rare in primary breast MALT lymphoma [ncbi , more ].
NANCY RICE
  • immunohistochemistryIn 2004, Susan E McNulty et al. applied p50 antibody to study the expression pattern of NFkappaB family members in human melanocytic cells of normal skin, benign intradermal naevus, and metastatic melanoma tissues [ncbi , more ].
Boehringer Mannheim
  • immunohistochemistryIn 2004, Sergio Mezzano et al. applied Boehringer Mannheim p50 antibody to study NF-kappaB in human diabetic nephropathy [ncbi , more ].
autogenbioclear
  • western blotIn 2003, N Foster et al. employed autogenbioclear p50 antibody to study the effect of induction of polymorphonuclear leukocytes by avirulent salmonella enterica on protection of pigs and human against salmonellosis in human fetal intestinal epithelial INT 407 cells [ncbi , more ].
Articles Reviewed
  1. Wei Li et al. (2010). "IL-32: a host proinflammatory factor against influenza viral replication is upregulated by aberrant epigenetic modifications during influenza A virus infection".PMID 20889550
  2. Saira Ali et al. (2010). "Requirement for nuclear factor kappa B signalling in the interleukin-1-induced expression of the CCAAT/enhancer binding protein-delta gene in hepatocytes".PMID 19800021
  3. Junfang Wu et al. (2010). "Phosphatidylinositol 3-kinase/protein kinase Cdelta activation induces close homolog of adhesion molecule L1 (CHL1) expression in cultured astrocytes".PMID 19672967
  4. Derek S Wheeler et al. (2009). "Extracellular Hsp72, an endogenous DAMP, is released by virally infected airway epithelial cells and activates neutrophils via Toll-like receptor (TLR)-4".PMID 19405961
  5. Chad Myskiw et al. (2009). "Vaccinia virus E3 suppresses expression of diverse cytokines through inhibition of the PKR, NF-kappaB, and IRF3 pathways".PMID 19369349
  6. Serena Ghisletti et al. (2009). "Cooperative NCoR/SMRT interactions establish a corepressor-based strategy for integration of inflammatory and anti-inflammatory signaling pathways".PMID 19299558
  7. Flavia Bazzoni et al. (2009). "Induction and regulatory function of miR-9 in human monocytes and neutrophils exposed to proinflammatory signals".PMID 19289835
  8. Takashi Kobayashi et al. (2009). "TRAF6 is required for generation of the B-1a B cell compartment as well as T cell-dependent and -independent humoral immune responses".PMID 19270748
  9. Anne Tove Brenne et al. (2009). "High expression of BCL3 in human myeloma cells is associated with increased proliferation and inferior prognosis".PMID 19191868
  10. S J Veuger et al. (2009). "Ionizing radiation-induced NF-kappaB activation requires PARP-1 function to confer radioresistance".PMID 19060926
  11. Xiaoping Chen et al. (2009). "RelB sustains IkappaBalpha expression during endotoxin tolerance".PMID 19020113
  12. I Paz-Priel et al. (2009). "C/EBPalpha or C/EBPalpha oncoproteins regulate the intrinsic and extrinsic apoptotic pathways by direct interaction with NF-kappaB p50 bound to the bcl-2 and FLIP gene promoters".PMID 18987666
  13. Susan Nozell et al. (2008). "The ING4 tumor suppressor attenuates NF-kappaB activity at the promoters of target genes".PMID 18779315
  14. Alessio Iannetti et al. (2008). "The neutrophil gelatinase-associated lipocalin (NGAL), a NF-kappaB-regulated gene, is a survival factor for thyroid neoplastic cells".PMID 18768801
  15. Celine Cosseau et al. (2008). "The commensal Streptococcus salivarius K12 downregulates the innate immune responses of human epithelial cells and promotes host-microbe homeostasis".PMID 18625732
  16. Xiaoyong Bao et al. (2008). "Human metapneumovirus glycoprotein G inhibits innate immune responses".PMID 18516301
  17. Pilar Gallel et al. (2008). "Nuclear factor-kappaB activation is associated with somatic and germ line RET mutations in medullary thyroid carcinoma".PMID 18508109
  18. Sabine Wolter et al. (2008). "c-Jun controls histone modifications, NF-kappaB recruitment, and RNA polymerase II function to activate the ccl2 gene".PMID 18443042
  19. Nobuyuki Kikuno et al. (2008). "Genistein mediated histone acetylation and demethylation activates tumor suppressor genes in prostate cancer cells".PMID 18431742
  20. Karen G Calfee-Mason et al. (2008). "Role of the p50 subunit of NF-kappaB in vitamin E-induced changes in mice treated with the peroxisome proliferator, ciprofibrate".PMID 18336980
  21. Binhui Wu et al. (2008). "Proteomics analysis of immunoprecipitated proteins associated with the oncogenic kinase cot".PMID 18319612
  22. Patricia Méndez-Samperio et al. (2008). "Mycobacterium bovis bacillus Calmette-Guerin induces CCL5 secretion via the Toll-like receptor 2-NF-kappaB and -Jun N-terminal kinase signaling pathways".PMID 17989335
  23. Natalie J Thornburg et al. (2007). "Induction of epidermal growth factor receptor expression by Epstein-Barr virus latent membrane protein 1 C-terminal-activating region 1 is mediated by NF-kappaB p50 homodimer/Bcl-3 complexes".PMID 17881446
  24. Mathias Laga et al. (2007). "Methylglyoxal suppresses TNF-alpha-induced NF-kappaB activation by inhibiting NF-kappaB DNA-binding".PMID 17617381
  25. M V P Nadella et al. (2007). "Transcriptional regulation of parathyroid hormone-related protein promoter P2 by NF-kappaB in adult T-cell leukemia/lymphoma".PMID 17554373
  26. Meilang Xue et al. (2007). "Endothelial protein C receptor is overexpressed in rheumatoid arthritic (RA) synovium and mediates the anti-inflammatory effects of activated protein C in RA monocytes".PMID 17491095
  27. Naoko Kanda et al. (2007). "IL-18 enhances IFN-gamma-induced production of CXCL9, CXCL10, and CXCL11 in human keratinocytes".PMID 17274000
  28. Yutaka Kida et al. (2007). "Serratia marcescens serralysin induces inflammatory responses through protease-activated receptor 2".PMID 17043106
  29. Yutao Yan et al. (2007). "Characterization of the human intestinal CD98 promoter and its regulation by interferon-gamma".PMID 17023546
  30. Narayanan Parameswaran et al. (2006). "Arrestin-2 and G protein-coupled receptor kinase 5 interact with NFkappaB1 p105 and negatively regulate lipopolysaccharide-stimulated ERK1/2 activation in macrophages".PMID 16980301
  31. Sameer S Talwalkar et al. (2006). "MALT1 gene rearrangements and NF-kappaB activation involving p65 and p50 are absent or rare in primary MALT lymphomas of the breast".PMID 16917511
  32. Jing Mi et al. (2006). "H1 RNA polymerase III promoter-driven expression of an RNA aptamer leads to high-level inhibition of intracellular protein activity".PMID 16855294
  33. H Thomas Lee et al. (2006). "A3 adenosine receptor activation decreases mortality and renal and hepatic injury in murine septic peritonitis".PMID 16728466
  34. Michael A James et al. (2006). "Human papillomavirus type 16 E6 activates NF-kappaB, induces cIAP-2 expression, and protects against apoptosis in a PDZ binding motif-dependent manner".PMID 16699010
  35. Lakshmanan Ganesh et al. (2006). "Protein methyltransferase 2 inhibits NF-kappaB function and promotes apoptosis".PMID 16648481
  36. Kazi Nazrul Islam et al. (2006). "Permissive effects of oxygen on cyclic AMP and interleukin-1 stimulation of surfactant protein A gene expression are mediated by epigenetic mechanisms".PMID 16581766
  37. Nobutaka Suzuki et al. (2006). "A critical role for the innate immune signaling molecule IRAK-4 in T cell activation".PMID 16574867
  38. Yoon Jae Song et al. (2006). "IL-1 receptor-associated kinase 1 is critical for latent membrane protein 1-induced p65/RelA serine 536 phosphorylation and NF-kappaB activation".PMID 16477006
  39. Susana Guerra et al. (2006). "Host response to the attenuated poxvirus vector NYVAC: upregulation of apoptotic genes and NF-kappaB-responsive genes in infected HeLa cells".PMID 16379000
  40. Rongqian Wu et al. (2005). "Ghrelin improves tissue perfusion in severe sepsis via downregulation of endothelin-1".PMID 16018991
  41. Sewon Kang et al. (2005). "Inflammation and extracellular matrix degradation mediated by activated transcription factors nuclear factor-kappaB and activator protein-1 in inflammatory acne lesions in vivo".PMID 15920154
  42. N A C S Wong et al. (2005). "CDX1 is an important molecular mediator of Barrett's metaplasia".PMID 15894614
  43. Yushi Bai et al. (2005). "Persistent nuclear factor-kappa B activation in Ucp2-/- mice leads to enhanced nitric oxide and inflammatory cytokine production".PMID 15757894
  44. Jinke Wang et al. (2005). "Exonuclease III protection assay with FRET probe for detecting DNA-binding proteins".PMID 15687381
  45. Fengjun Wang et al. (2005). "Interferon-gamma and tumor necrosis factor-alpha synergize to induce intestinal epithelial barrier dysfunction by up-regulating myosin light chain kinase expression".PMID 15681825
  46. Olivier Kassel et al. (2004). "A nuclear isoform of the focal adhesion LIM-domain protein Trip6 integrates activating and repressing signals at AP-1- and NF-kappaB-regulated promoters".PMID 15489293
  47. Jongmin Lee et al. (2004). "Transglutaminase 2 induces nuclear factor-kappaB activation via a novel pathway in BV-2 microglia".PMID 15471861
  48. Sergio Mezzano et al. (2004). "NF-kappaB activation and overexpression of regulated genes in human diabetic nephropathy".PMID 15280531
  49. Lea Madi et al. (2004). "The A3 adenosine receptor is highly expressed in tumor versus normal cells: potential target for tumor growth inhibition".PMID 15240539
  50. Mary H Ritchie et al. (2004). "A role for NF-kappa B binding motifs in the differential induction of chemokine gene expression in human corneal epithelial cells".PMID 15223809
  51. Chun Fung Chan et al. (2004). "Evaluation of nuclear factor-kappaB, urokinase-type plasminogen activator, and HBx and their clinicopathological significance in hepatocellular carcinoma".PMID 15217951
  52. S R Walmsley et al. (2004). "Characterization of the survival effect of tumour necrosis factor-alpha in human neutrophils".PMID 15157159
  53. Susan E McNulty et al. (2004). "Comparative expression of NFkappaB proteins in melanocytes of normal skin vs. benign intradermal naevus and human metastatic melanoma biopsies".PMID 15016307
  54. Jun Zhang et al. (2004). "Identification of a ZU5 and death domain-containing inhibitor of NF-kappaB".PMID 14769797
  55. Deok Soo Son et al. (2004). "Tumor necrosis factor-alpha induces serum amyloid A3 in mouse granulosa cells".PMID 14749357
  56. Shai Cohen et al. (2004). "Dual effects of IkappaB kinase beta-mediated phosphorylation on p105 Fate: SCF(beta-TrCP)-dependent degradation and SCF(beta-TrCP)-independent processing".PMID 14673179
  57. Takeaki Kaneko et al. (2003). "Induction of Tissue Factor Expression in Endothelial Cells by Basic Fibroblast Growth Factor and its Modulation by Fenofibric acid".PMID 14613528
  58. M A Christine Pratt et al. (2003). "Estrogen withdrawal-induced NF-kappaB activity and bcl-3 expression in breast cancer cells: roles in growth and hormone independence".PMID 12972607
  59. Arnaud Parcellier et al. (2003). "HSP27 is a ubiquitin-binding protein involved in I-kappaBalpha proteasomal degradation".PMID 12897149
  60. Harald Jakob Maier et al. (2003). "Critical role of RelB serine 368 for dimerization and p100 stabilization".PMID 12874295
  61. Ina Poser et al. (2003). "Upregulation of HMG1 leads to melanoma inhibitory activity expression in malignant melanoma cells and contributes to their malignancy phenotype".PMID 12665595
  62. N Foster et al. (2003). "Rapid protection of gnotobiotic pigs against experimental salmonellosis following induction of polymorphonuclear leukocytes by avirulent Salmonella enterica".PMID 12654840
  63. Virginia L Vega et al. (2003). "Geldanamycin treatment ameliorates the response to LPS in murine macrophages by decreasing CD14 surface expression".PMID 12589068
  64. Peter Starkel et al. (2003). "Expression and DNA-binding activity of signal transducer and activator of transcription 3 in alcoholic cirrhosis compared to normal liver and primary biliary cirrhosis in humans".PMID 12547716
  65. Kim Estell et al. (2003). "Plasma membrane CFTR regulates RANTES expression via its C-terminal PDZ-interacting motif".PMID 12509457
  66. Yutaka Kida et al. (2002). "Opposing roles of activator protein-1 and CCAAT/enhancer binding protein beta in the regulation of inducible granulysin gene expression in a human monocytic cell line, THP-1".PMID 12460196
  67. Rosemary Kiernan et al. (2003). "Post-activation turn-off of NF-kappa B-dependent transcription is regulated by acetylation of p65".PMID 12419806
  68. Christos Chadjichristos et al. (2002). "Down-regulation of human type II collagen gene expression by transforming growth factor-beta 1 (TGF-beta 1) in articular chondrocytes involves SP3/SP1 ratio".PMID 12186868
  69. Sergio D Catz et al. (2002). "JFC1 is transcriptionally activated by nuclear factor-kappaB and up-regulated by tumour necrosis factor alpha in prostate carcinoma cells".PMID 12137562
  70. Michael A Zimmerman et al. (2002). "Interleukin-11 attenuates human vascular smooth muscle cell proliferation".PMID 12063288
  71. Pascal Knuefermann et al. (2002). "Myotrophin/V-1, a protein up-regulated in the failing human heart and in postnatal cerebellum, converts NFkappa B p50-p65 heterodimers to p50-p50 and p65-p65 homodimers".PMID 11971907
  72. Charlie D Chen et al. (2002). "NF-kappa B activates prostate-specific antigen expression and is upregulated in androgen-independent prostate cancer".PMID 11909978
  73. Runqing Lu et al. (2002). "Stimulation of IRF-7 gene expression by tumor necrosis factor alpha: requirement for NFkappa B transcription factor and gene accessibility".PMID 11877397
  74. Chiara Fiorentini et al. (2002). "Nerve growth factor regulates dopamine D(2) receptor expression in prolactinoma cell lines via p75(NGFR)-mediated activation of nuclear factor-kappaB".PMID 11818506
  75. A M Al-Zoubi et al. (2001). "Contrasting effects of IG20 and its splice isoforms, MADD and DENN-SV, on tumor necrosis factor alpha-induced apoptosis and activation of caspase-8 and -3".PMID 11577081
  76. M Ruiz-Ortega et al. (2001). "Systemic infusion of angiotensin II into normal rats activates nuclear factor-kappaB and AP-1 in the kidney: role of AT(1) and AT(2) receptors".PMID 11337372